A Phase II Randomized Open Label Study of KLH-2109 in Patients With Endometriosis

A Multicenter, Randomized, Open Label Phase II Study of KLH-2109 in Patients With Endometriosis(3)

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01629420

Enrollment

Registered

2012-06-27

Start date

Unknown

Completion date

Unknown

Last updated

2014-05-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endometriosis

Keywords

Gonadotropin-Releasing Hormone (GnRH) antagonist

Brief summary

The purpose of this study is to evaluate the efficacy and safety of KLH-2109 in patients with endometriosis.

Interventions

DRUGKLH-2109

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Age

20 Years to No maximum

Healthy volunteers

Inclusion criteria

* Female patients with endometriosis

Exclusion criteria

* Patients with clinically significant hepatic, renal, or cardiovascular dysfunction

Design outcomes

Primary

Measure	Time frame
The severity score of the pelvic pain	8 weeks

Countries

Japan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026